Press Releases

 
Press Releases
  Date Title and Summary View
Jan 3, 2017
Directed Against a Validated TCR Target in Solid Tumors Built on the National Cancer Institute Proof of Concept Work and Optimized to Include Next Generation T-cell Manufacturing Technologies SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharm...
Dec 19, 2016
Kite to Appeal USPTO Declining to Revoke Narrow Patent Against Certain CAR-T Constructs having a Single Specified CD28 Sequence Kite Successfully Defeats 3rd Party Challenge to Kite CAR-T Patent which Covers Methods for Using Modified T cells Containing scFv Binding Elements and Other ...
Dec 13, 2016
Strategic Partnership will Connect Vitruvian's Cloud-Based Software with Kite Pharma's Kite Konnect™ Platform to Enable Commercial-Scale Logistics for T-cell Therapies SANTA MONICA, Calif. and SAN FRANCISCO--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq: KITE) and Vitruvian Networks, Inc...
Dec 12, 2016
Publication Describes Work Pertaining to the Cooperative Research and Development Agreement (CRADA) between the National Institutes of Health (NIH) and Kite Pharma Kite Pharma Has an Exclusive License from NIH to Multiple T Cell Receptor (TCR) Product Candidates Targeting Mutant KRAS t...
Dec 6, 2016
76 Percent of Patients with Diffuse Large B-Cell Lymphoma Achieved Objective Response (p ...
Dec 4, 2016
•First CAR-T Therapy BLA Filing Initiated with the U.S. Food and Drug Administration •Company Expects to Complete BLA Submission by the end of Q1 2017 •United States Adopted Name, or USAN, for KTE-C19 will be axicabtagene ciloleucel ...
Dec 4, 2016
• 100 Percent of Responders Tested Negative for Minimal Residual Disease (MRD) SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that 82 percent of patients (9 out of 11) achieved complete remission or complete remission wi...
Dec 1, 2016
Company Strengthens Supply Chain Operations as it Prepares for Potential Approval and Launch of KTE-C19 for Aggressive non-Hodgkin Lymphoma by the U.S. Food and Drug Administration in 2017 SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq: KITE) today a...
Nov 21, 2016
KTE-C19 Significantly Improved Objective Response Rate in Patients with Chemorefractory DLBCL at Pre-Defined Interim Analysis Represents One of Only Six Abstracts Accepted as a Late-Breaking Presentation SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kit...
Nov 9, 2016
Company Announces Plans to Initiate a Rolling Submission of the Biologics License Application for KTE-C19 with the U.S. Food and Drug Administration for an Expanded Indication of Aggressive Non-Hodgkin Lymphoma in December 2016 with a Targeted Completion in Q1 2017 Potential Approval a...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase